Introducing Technology
Preserving Sight for Everyone
Confidential - Proprietary information of El-Vision Ltd. Contact:
Mr. Arthur Rabner: 42 Ha-Rakevet Str, Tel-Aviv 67770, Israel.
[email protected] +972-54-4447948
The Company
Operation Started: Aug 2006
CEO: Mr. Tal Dilian
CTO and Founder: Mr. Arthur Rabner
Financing: About $1M (IL OCS, IL/US Private)
Full Time Employees: 6
2
Ophthalmic Arena Bottlenecks
1.
Underserved Populations (aging, diabetes, low
awareness/income, remote areas)
2.
Today Vision Screening services are not effective
(mismatching ~30% - 60% of cases)
3.
Tight Competition between Eye Care Professionals
(50,000 in US )
4.
Tight Competition on High End Diagnostics
Instruments Market (Total $1.5B in US, 10% growth)
3
The El-Vision Solution
All-In-One Device for
High-End Vision &
Eyes Screening
During 5 – 15 minutes
The Vision of Final Device
Communication
Link
Eye Care office
with plug-in El-Vision’s SW into EMR
Eye care
assistant
Patient
under
Test
Examination is performed in
an office or in any other place
4
El-Vision’s Opportunity
Manufacturers
Instruments
$1.5B/year in US
10% growth
Users
Old Players
Low End
(< $5K)
Vision150,000
Screeners
El-Vision
Old Players
Startups
Old Players
Leaders
Leaders
Startups
Leaders
Sales Growth
Competition
promotion
High End Vision
Med Range
& Eyes Screener
(<$25K)
High End:
( > $25K )
New Players
Primary Care
Increased
Physicians
Demand
50,000
Ophthalmic delegate
delegate Optometrists
Ophthalmic
Specific
Specific Disease
Disease
Assistants
Assistants
Ophthalmologists specialization
Experts
Experts
Extended
Audience
Fight for customers
Population
=================
Preliminary
exam
Comprehensive
direct
Prompt Vision & Eyes More
Cheap
Screening
Treated
Underserved Remote
Users
Treated
refer
•Prescription
General ODs / OMDs
•Primary Eye Care More
•Follow-up
•Special
•Special Eye
Eye Care
Care
•Follow-up
•Follow-up
5
El-Vision: 12 months Milestones / Financials
VATest-rev2
Prototype
part1
VATest Production Version
part2
part3
Regulation Activities
VATest FDA Application
Proceeds
Aug09
Jul09
Jun09
May09
Mar09
Feb09
Jan09
VC/Corporate Funds Raising (round A)
Dec08
Nov08
Oct08
$1M raising
Sep08
Funds Raising
part3 (in US)
Apr09
Clinical Studies
VATest-rev3/4
$50K $50K $50K $70K $60K $90K $90K $100K $110K $120K $130K $120K
$1,040,000
6
Thank you
More detailed information is
available, please contact the CTO
of El-Vision, Arthur Rabner:
[email protected]